More objective measures of RA disease activity and progression could aid in the identification of predictive biomarkers [27], [28], and objective measures of joint inflammation are expected to associate more robustly with molecular predictors of response to a TNF blocker like infliximab. The gene discussed is TNF; the disease is rheumatoid arthritis.